- BIIB -0.08%
Biogen Q2 Earnings: Beats Consensus, Lifts 2024 Profit Forecast As New Drug Launches Expected To Offset Decline In Multiple...
Yahoo Finance · 6 days ago
Search results
- 199.98Add to watchlist-0.15 (-0.08%)As of Wed. Aug 7, 2024 12:43 PM EDT · Nasdaq Real Time Price (USD) · Market open
- Open201.52High203.50Low199.89
- Mkt Cap29.13BP/E (TTM)25.19Div & YieldN/A & N/A
- Prev. Close200.1352 Wk. Low189.4452 Wk. High276.52
What analysts are sayingTop storiesRelated stocks
Biogen is a leading global biotechnology company that pioneers science and drives innovations for complex and devastating diseases. Biogen is advancing a pipeline of potential therapies across neurology, neuropsychiatry, specialized immunology and rare disease and remains acutely focused on its purpose of serving humanity through science while ...
Founded in 1978, Biogen has pioneered multiple breakthrough innovations including a broad portfolio of medicines to treat multiple sclerosis, the first approved treatment for spinal muscular atrophy, and two co-developed treatments to address a defining pathology of Alzheimer’s disease.
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally.
At Biogen, our mission is clear: we are pioneers in neuroscience. Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related adjacencies.
Apr 25, 2023 · The Food and Drug Administration on Tuesday authorized the first drug for a rare genetic form of the neurological disorder A.L.S., despite uncertainty about the treatment’s effectiveness.
Jun 7, 2021 · The Food and Drug Administration on Monday approved Biogen 's Alzheimer's disease drug aducanumab, making it the first medication cleared by U.S. regulators to slow cognitive decline in people ...
Breaking New Ground With Science. With a strong focus on difficult-to-treat diseases, our pipeline is focused on research in therapeutic areas where we believe we have the best opportunity to deliver transformational medicines to patients and protect public health.
Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the discovery, development, and delivery of therapies for the treatment of neurological diseases to patients worldwide. Biogen operates in Argentina, Brazil, Canada, China, France, Germany, Hungary, India, Italy, Japan ...
FDA Approves LEQEMBI™ (lecanemab-irmb) Under the Accelerated Approval Pathway for the Treatment of Alzheimer's Disease. January 6, 2023. PDF Version. Accelerated Approval is based on Phase 2 data showing a reduction in amyloid-beta plaques in early AD patients treated with LEQEMBI™.
6 days ago · The Biogen headquarters in Cambridge, Massachusetts. Biogen Inc. raised its profit outlook after cost-cuts and faster sales of new drugs boosted second-quarter earnings. The biotech company now ...
